Redhill Biopharma Ltd. RDHL
Annual
Quarterly
FY2024 · ended Dec 31, 2024 · Revenue $8.04M, +23.2% YoY · Filed Apr 10, 2025
Redhill Biopharma Ltd. (RDHL) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2024, which ended Dec 31, 2024, it reported revenue of $8.0 million and a net loss of $8.3 million. Free cash flow was -$9.4 million. As of Dec 31, 2024 it held $4.6 million in cash and investments and $356,000 in total debt.
Revenue
$8.04M
+23.2% vs prior year
Net income
$-8.27M
-134.6% vs prior year
Operating cash flow
$-9.37M
+73.8% vs prior year
Free cash flow
$-9.38M
+73.8% vs prior year
EPS
$0.00
-100.0% vs prior year
Dividend per share
None
Shares outstanding
50.92B
+294.8% vs prior year
Net cash
$4.26M
FY 2024
Operating margin
-181.7%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RDHL (Nasdaq)
- Incorporated in
- Israel
- Headquarters
- Tel Aviv, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1553846
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $8.0M | $6.5M | $61.8M | $85.8M | $64.4M |
| Operating income | -$14.6M | $12.6M | -$42.8M | -$81.1M | -$63.7M |
| Net income | -$8.3M | $23.9M | -$71.7M | -$97.7M | -$76.2M |
| Diluted EPS | $0.00 | $0.01 | -$0.12 | -$0.21 | — |
| Operating cash flow | -$9.4M | -$35.8M | -$29.2M | -$65.0M | -$48.6M |
| Free cash flow | -$9.4M | -$35.8M | -$29.4M | -$65.2M | -$49.0M |
| Total assets | $18.0M | $23.0M | $158.9M | $181.2M | $180.2M |
| Total liabilities | $22.7M | $21.0M | $207.3M | $172.3M | $166.4M |
| Stockholders' equity | -$4.7M | $2.1M | -$48.4M | $8.9M | $13.9M |
| Cash and investments | $4.6M | $5.6M | $20.0M | $29.5M | $29.3M |
| Total debt | $356,000 | $1.2M | $122.7M | $87.8M | $86.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 21, 2026 | Oct 21, 2026 |
| 6-K | Current report (foreign issuer) | Oct 19, 2026 | Oct 19, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
| 6-K | Current report (foreign issuer) | Oct 7, 2026 | Oct 7, 2026 |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
All 1000 Redhill Biopharma Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.